PL378354A1 - Analogi nukleozydów przeciwwirusowych i sposoby leczenia zakażeń wirusowych, zwłaszcza zakażeń wirusem HIV - Google Patents

Analogi nukleozydów przeciwwirusowych i sposoby leczenia zakażeń wirusowych, zwłaszcza zakażeń wirusem HIV

Info

Publication number
PL378354A1
PL378354A1 PL378354A PL37835404A PL378354A1 PL 378354 A1 PL378354 A1 PL 378354A1 PL 378354 A PL378354 A PL 378354A PL 37835404 A PL37835404 A PL 37835404A PL 378354 A1 PL378354 A1 PL 378354A1
Authority
PL
Poland
Prior art keywords
infections
viral
methods
nucleoside analogs
especially hiv
Prior art date
Application number
PL378354A
Other languages
English (en)
Other versions
PL219609B1 (pl
Inventor
Yung-Chi Cheng
Hiromichi Tanaka
Masanori Baba
Original Assignee
Yale University
Hiromichi Tanaka
Masanori Baba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Hiromichi Tanaka, Masanori Baba filed Critical Yale University
Publication of PL378354A1 publication Critical patent/PL378354A1/pl
Publication of PL219609B1 publication Critical patent/PL219609B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL378354A 2003-02-19 2004-02-18 Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania PL219609B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44855403P 2003-02-19 2003-02-19

Publications (2)

Publication Number Publication Date
PL378354A1 true PL378354A1 (pl) 2006-03-20
PL219609B1 PL219609B1 (pl) 2015-06-30

Family

ID=34115263

Family Applications (2)

Application Number Title Priority Date Filing Date
PL378354A PL219609B1 (pl) 2003-02-19 2004-02-18 Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
PL398295A PL398295A1 (pl) 2003-02-19 2004-02-28 Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL398295A PL398295A1 (pl) 2003-02-19 2004-02-28 Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania

Country Status (14)

Country Link
US (3) US7589078B2 (pl)
EP (2) EP2298783B1 (pl)
JP (1) JP4980059B2 (pl)
KR (2) KR20110079783A (pl)
CN (2) CN1777432B (pl)
AU (1) AU2004260630B2 (pl)
BR (1) BRPI0407374A (pl)
CA (1) CA2514466C (pl)
EA (1) EA012844B1 (pl)
HK (1) HK1087341A1 (pl)
MX (1) MXPA05008736A (pl)
PL (2) PL219609B1 (pl)
WO (1) WO2005011709A1 (pl)
ZA (1) ZA200506630B (pl)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010489A1 (en) 2002-04-26 2007-01-11 Arimilli Murty N Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
WO2005011709A1 (en) 2003-02-19 2005-02-10 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
NZ542342A (en) * 2003-04-25 2009-05-31 Gilead Sciences Inc Antiviral phosphonate analogs
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
WO2004096287A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
AU2004286239A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7427624B2 (en) * 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
KR20060127906A (ko) * 2003-12-22 2006-12-13 길리애드 사이언시즈, 인코포레이티드 4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
US20070281907A1 (en) * 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EP3539546A1 (en) 2004-07-27 2019-09-18 Gilead Sciences, Inc. Phosphonate analogs of hiv inhibitor compounds
EP1802315A2 (en) * 2004-10-19 2007-07-04 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
EP1937825B1 (en) 2005-09-26 2016-12-21 Gilead Pharmasset LLC Modified 4'-nucleosides as antiviral agents
CN101511375B (zh) * 2005-12-02 2012-09-05 耶鲁大学 L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
WO2007065032A2 (en) * 2005-12-02 2007-06-07 The Regents Of The University Of California Compounds and methods for inhibiting viral entry
US20080078560A1 (en) * 2006-10-02 2008-04-03 Kevin Hall Motor seal
CN101796040A (zh) * 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
US9051288B2 (en) * 2007-12-27 2015-06-09 Oncolys Biopharma, Inc. Method for producing 4′-ethynyl d4T
JP5485138B2 (ja) * 2008-03-28 2014-05-07 浜理薬品工業株式会社 エチニルチミジン化合物の精製方法
EP2277878B1 (en) * 2008-04-10 2014-09-17 Hamari Chemicals, Ltd. Process for production of ethynylthymidine compound using 5-methyluridine as starting raw material
AU2009268681B2 (en) * 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
CN102348712A (zh) * 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
BRPI1005828A2 (pt) * 2009-02-27 2017-07-18 Siga Tech Inc composição farmacêutica; método para o tratamento ou a profilaxia de uma infecção viral ou doença associada com a mesma; composto; método para a preparação de uma mistura de terc-butil(4e)-4-(hidroximetileno)-5-oxoazepano-1-carboxilato e terc-butil (3e)-3-(hidroximetileno)-4-oxoazepano-1-carboxilato; método para a preparação de uma mistura de terc-butil 3-ciano-2-tioxo-1,2,5,6,8,9-hexaidro-1h-pirido [2,3-d] azepina-7-carboxilato e terc-butil 3-ciano-2-tioxo-1,2,5,7,8,9-hexaidro-6h-pirido [3,2-c] azepina-6-carboxilato; método para a preparação de ácido 3-amino-7-terc-butiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4]tiazol-2-il)-amida; método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-7,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida; método para a preparação de ácido 3-amino-6-tercbutiloxicarbonil-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida e método para a preparação de ácido 3-amino-6,7,8,9-tetraidro-5h-1-tia-6,10-diaza-ciclohepta [f] indeno-2-carboxílico (5-fenil-[1,3,4] tiadiazol-2-il)-amida
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP5765536B2 (ja) 2010-02-15 2015-08-19 日産化学工業株式会社 β−グリコシド化合物の製造方法
US9212174B2 (en) 2010-02-15 2015-12-15 Nissan Chemical Industries, Ltd. Certain β-dihydrofuran derivatives
CN102906273B (zh) 2010-04-07 2014-11-05 日产化学工业株式会社 酰氧基吡喃酮化合物的制造方法、炔烃化合物的制造方法及二氢呋喃化合物的制造方法
WO2012048271A1 (en) * 2010-10-08 2012-04-12 The Board Of Trustees Of The University Of Illinois Phosphoramidate derivatization of inorganic polyphosphates and methods
WO2012166645A1 (en) * 2011-06-01 2012-12-06 Syndax Pharmaceuticals, Inc. Prodrugs of azacitidine 5' -diphosphate
WO2013066991A1 (en) * 2011-10-31 2013-05-10 Inhibitex, Inc. Crystalline solvates of nucleoside phosphoroamidates, their stereoselective preparation, novel intermediates thereof, and their use in the treatment of viral disease
AP2014007796A0 (en) 2011-12-22 2014-07-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013177243A1 (en) 2012-05-23 2013-11-28 Bristol-Myers Squibb Company Sulfilimine and sulphoxide methods for producing festinavir
WO2014172264A1 (en) 2013-04-16 2014-10-23 Bristol-Myers Squibb Company Method for producing festinavir using 5-methyluridine as starting material
GB201306947D0 (en) * 2013-04-17 2013-05-29 Univ Leuven Kath Novel antiviral compounds
WO2014201122A1 (en) 2013-06-13 2014-12-18 Bristol-Myers Squibb Company Tert-butyl-sulphoxide method for producing festinavir
US10683321B2 (en) * 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
JP6671355B2 (ja) * 2014-09-26 2020-03-25 リボサイエンス・エルエルシー 呼吸器多核体ウイルスのｒｎａ複製の阻害剤としての４’‐ビニル置換ヌクレオシド誘導体
WO2016069489A1 (en) * 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
EP3377177A2 (en) 2015-11-20 2018-09-26 VIIV Healthcare UK(No.4) Limited Hiv maturation inhibitor formulations
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
KR20220146668A (ko) 2016-09-07 2022-11-01 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
KR20200056420A (ko) * 2017-09-21 2020-05-22 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
KR101893988B1 (ko) 2018-05-16 2018-08-31 (주)에빅스젠 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물
EP3831388B1 (en) * 2018-07-27 2024-02-28 FUJIFILM Corporation Cyclopentenyl purine derivative or salt thereof for use in suppressing adenovirus
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
CN109761842B (zh) * 2019-02-01 2021-11-30 浙江工业大学 α-F-β-NHAc-羰基化合物的合成方法
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
KR20230130898A (ko) 2022-03-04 2023-09-12 동아대학교 산학협력단 N4-이소부티릴옥시시티딘 모방체 합성과 이의 항바이러스 용도를 포함하는 바이러스 감염 치료용 조성물
WO2024015916A2 (en) * 2022-07-13 2024-01-18 Thomas Jefferson University 4'-alkyne-2'-deoxycytidine-based compounds and anti-cancer uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5179084A (en) 1989-04-10 1993-01-12 Nippon Kayaku Kabushiki Kaisha Antiviral phosphoric acid esters of oxetanocins
US5192749A (en) * 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
US5739396A (en) * 1991-12-09 1998-04-14 Stanford University Asymmetric ligands useful for transition metal catalyzed bond forming reactions
JPH05230058A (ja) * 1992-02-24 1993-09-07 Yamasa Shoyu Co Ltd ４’−炭素置換ピリミジンヌクレオシド及びその製造法
ZA931934B (en) 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
JPH0680688A (ja) * 1992-09-03 1994-03-22 Asahi Breweries Ltd ４’−メチルヌクレオシド誘導体
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
RU2130029C1 (ru) * 1994-12-13 1999-05-10 Тайхо Фармасьютикал Ко., Лтд. 3'-замещенные производные нуклеозида, способ их получения (варианты), лекарственное средство, способ лечения и профилактики
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
ATE234318T1 (de) * 1996-05-16 2003-03-15 Taiho Pharmaceutical Co Ltd D-pentofuranose-derivate und verfahren zu ihrer herstellung
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5821242A (en) 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
AU6358898A (en) 1996-09-09 1998-04-17 Alexander V Kabanov Fluorinated copolymeric pharmaceutical adjuncts
JP3792005B2 (ja) * 1997-04-24 2006-06-28 彰 松田 ２−デオキシ−３−エチニル−β−Ｄ−リボフラノシル誘導体
WO1998055120A1 (en) 1997-06-04 1998-12-10 Eli Lilly And Company Anti-viral compounds
JP4211901B2 (ja) * 1998-06-08 2009-01-21 ヤマサ醤油株式会社 ４’−メチルヌクレオシド化合物
AU751457B2 (en) 1998-09-25 2002-08-15 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
WO2000069876A1 (en) 1999-05-12 2000-11-23 Yamasa Corporation 4'-c-ethynyl pyrimidine nucleosides
US6240690B1 (en) 2000-02-02 2001-06-05 Roof & Metal Systems, Inc. Vented metal roof
RU2182013C1 (ru) 2001-03-05 2002-05-10 Казанцева Наталья Вениаминовна Способ лечения нейродегенеративных заболеваний мозга
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1438054A4 (en) * 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
AU2002341942A1 (en) * 2002-01-17 2003-09-02 Ribapharm Inc. Sugar modified nucleosides as viral replication inhibitors
WO2005011709A1 (en) * 2003-02-19 2005-02-10 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections

Also Published As

Publication number Publication date
US7589078B2 (en) 2009-09-15
KR20060026402A (ko) 2006-03-23
JP4980059B2 (ja) 2012-07-18
BRPI0407374A (pt) 2006-01-10
KR20110079783A (ko) 2011-07-07
EP1653976A4 (en) 2009-07-29
KR101228503B1 (ko) 2013-01-31
EP2298783A1 (en) 2011-03-23
CN1777432B (zh) 2011-06-08
US20100048500A1 (en) 2010-02-25
CA2514466C (en) 2015-05-26
WO2005011709A1 (en) 2005-02-10
EP2298783B1 (en) 2017-12-06
PL398295A1 (pl) 2012-05-21
US8193165B2 (en) 2012-06-05
US20120252751A1 (en) 2012-10-04
CA2514466A1 (en) 2005-02-10
CN102174038A (zh) 2011-09-07
CN1777432A (zh) 2006-05-24
HK1087341A1 (en) 2006-10-13
AU2004260630A1 (en) 2005-02-10
AU2004260630B2 (en) 2009-12-10
JP2006528972A (ja) 2006-12-28
EP1653976A1 (en) 2006-05-10
PL219609B1 (pl) 2015-06-30
MXPA05008736A (es) 2005-10-05
EA012844B1 (ru) 2009-12-30
US20040167096A1 (en) 2004-08-26
EA200501325A1 (ru) 2006-02-24
US9126971B2 (en) 2015-09-08
ZA200506630B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
PL378354A1 (pl) Analogi nukleozydów przeciwwirusowych i sposoby leczenia zakażeń wirusowych, zwłaszcza zakażeń wirusem HIV
AU2002364730A8 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
IL174685A0 (en) Nucleoside compounds for treating viral infections
IL164729A0 (en) Nucleoside derivatives for treating hepatitis c virus infection
EP1572097A4 (en) NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
EP1814898A4 (en) ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS OF TREATMENT INFLUENZA VIRAL INFECTIONS
WO2006075993A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
IL174684A0 (en) Nucleoside compounds for treating viral infections
AP2005003211A0 (en) 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
HK1100961A1 (en) Antisense antiviral compound and method for treating ssrna viral infection
EP1804812A4 (en) FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
IL178141A0 (en) Combinations for treating hiv infection
WO2004112687A3 (en) Antiviral acylguanidine compounds and methods
WO2005021568A3 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
AP2005003212A0 (en) Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections.
PL376454A1 (pl) Pochodne 1-acylo-pirolidynowe do leczenia zakażeńwirusowych
WO2008127364A3 (en) Antiviral compounds and use thereof
TW200640474A (en) Tricyclic-nucleoside compounds for treating viral infections
EP1817024A4 (en) ANDROGRAPHOLIDE DERIVATIVES FOR TREATING VIRAL INFECTIONS
HK1125305A1 (en) Methods for treating viral infections using polyamine analogs
EP1668145A4 (en) SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION
GB0329254D0 (en) Treatment of viral infections
WO2002094844A3 (en) Antiviral nucleosides
EP1660116A4 (en) METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
GB0329958D0 (en) Treatment of viral infections

Legal Events

Date Code Title Description
DISD Decisions on discontinuance of the proceedings of a derived patent or utility model

Ref document number: 398295